Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 3/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889867 | 1.00 | KMT2A (0.65) | KMT2AEPHX2TLR2MDM4TP53 | |
| SCHEMBL888350 | 1.00 | KMT2A (0.65) | KMT2AEPHX2TLR2MDM4TP53 | |
| SCHEMBL889810 | 0.89 | KMT2A (0.64) | KMT2AEPHX2TLR2CASP3 | |
| SCHEMBL13208112 | 0.89 | KMT2A (0.64) | KMT2AEPHX2TLR2CASP3 | |
| SCHEMBL6678183 | 0.89 | KMT2A (0.67) | KMT2AEPHX2TLR2CASP3TLR1 | |
| SCHEMBL12787716 | 0.87 | KMT2A (0.64) | KMT2AEPHX2TLR2CASP3TLR1 | |
| SCHEMBL13775067 | 0.86 | KMT2A (0.63) | KMT2AEPHX2TLR2MDM4TP53 | |
| SCHEMBL793384 | 0.86 | KMT2A (0.85) | KMT2AEPHX2TLR2CASP3TLR1 | |
| SCHEMBL2495884 | 0.85 | KMT2A (0.58) | KMT2AEPHX2TLR2 | |
| SCHEMBL1660910 | 0.85 | KMT2A (0.74) | KMT2AEPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8465921-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2013-06-18 | — | — | US | disclosed |
| US-20110275070-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | disclosed |
| US-7794945-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2010-09-14 | — | — | US | disclosed |
| EP-1144429-B1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH BIOSCIENCES INC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-7556923-B1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH BIOSCIENCES, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH BIOSCIENCES, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-6884584-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH BIOSCIENCES, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20050064463-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | DRUG ROYALTY LP1 (CA) | 2005-03-24 | — | — | US | disclosed |
| US-20040058322-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | US | disclosed |
| US-6492346-B1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6312894-B1 | HYBRIDIZATION OF OLIGONUCLEOTIDES AND MINOR GROOVE BINDER COMBINATION; WHERE THE MINOR GROOVE BINDER BINDS IN A NON-INTERCALATING MANNER WITH A HIGHER ASSOCIATION CONSTANT | EPOCH PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050064463-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | DDB1, LIG3, MSH2 | KMT2A 3342/4885EPHX2 3287/4885TLR2 4198/4885 |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | DDB1, LIG3, MSH2 | KMT2A 3342/4885EPHX2 3287/4885TLR2 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.